AcquisitionsJul 28, 2026, 04:07 PM
Abbott Completes $20.6B Exact Sciences Acquisition; Q2 Sales Up 13%
AI Summary
Abbott Laboratories completed its acquisition of Exact Sciences for approximately $20.6 billion in March 2026, significantly expanding its cancer diagnostics portfolio. This strategic move contributed to a 13.0% increase in Q2 2026 net sales to $12.59 billion. However, net earnings for the quarter decreased by 47.9% to $928 million, primarily due to higher interest expenses and amortization costs associated with the acquisition. The acquisition also led to a substantial increase in long-term debt and intangible assets on the balance sheet.
Key Highlights
- Completed acquisition of Exact Sciences for approximately $20.6 billion on March 23, 2026.
- Q2 2026 Net Sales increased 13.0% to $12.59 billion from $11.14 billion in Q2 2025.
- Q2 2026 Net Earnings decreased 47.9% to $928 million, down from $1.78 billion in Q2 2025.
- Long-term debt increased to $29.60 billion at June 30, 2026, from $9.90 billion at Dec 31, 2025.
- Diagnostic Products segment sales grew 42.3% to $3.09 billion in Q2 2026, including Cancer Diagnostics.
- Net cash from operating activities for H1 2026 was $3.80 billion, up from $3.46 billion in H1 2025.
- Goodwill increased by $11.4 billion and intangible assets by $12.3 billion due to the acquisition.
Price Impact
More from ABT